Publications by authors named "Hartmut Dohner"

Claim this Profile
A
ALIDHE phase 3b study design: ivosidenib + azacitidine in adults with newly diagnosed mutant acute myeloid leukemia.
Paresh Vyas, Sam Salek, Susana Vives, Christian Recher, Hartmut Döhner

Future Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient involvement in the design of ALIDHE: a study of ivosidenib + azacitidine in newly diagnosed mutant AML.
Samantha Nier, Jana Pelouchova, Ralph Hills, Sam Salek, Hélène Derrien

Future Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genetic and epigenetic alterations at secondary resistance after continued decitabine-based treatment of acute myeloid leukemia in the randomized phase II DECIDER trial.
Inga Hund, Maria Elena Hess, Geoffroy Andrieux, Julia Stomper, Gabriele Greve

Leukemia· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A noncoding mutation in the NOTCH1 gene initiates oncogenic NOTCH signaling via wild-type NICD stabilization in CLL.
Min Guo, Tugba Memis, Alena Sophie Ehrmann, Anselm Pittrof, Bernd Baumann

Blood· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term results from the AGILE study of azacitidine plus ivosidenib vs placebo in newly diagnosed IDH1-mutated AML.
Pau Montesinos, Dylan M Marchione, Christian Recher, Michael Heuser, Susana Vives

Blood Adv· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Arsenic Trioxide and All-Trans Retinoic Acid Combination Therapy for the Treatment of High-Risk Acute Promyelocytic Leukemia: Results From the APOLLO Trial.
Uwe Platzbecker, Lionel Adès, Pau Montesinos, Emanuele Ammatuna, Pierre Fenaux

J Clin Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential prognostic impact of myelodysplasia-related gene mutations in a European cohort of 4978 intensively treated AML patients.
Marius Bill, Jan-Niklas Eckardt, Konstanze Döhner, Maximillian-Alexander Röhnert, Christian Rausch

Leukemia· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multimodal and Data-Driven Assessment of Myeloid Neoplasms Refines Classification across Disease States.
Curtis A Lachowiez, Georgios Asimomitis, Elsa Bernard, Sean M Devlin, Yanis Tazi

Blood Cancer Discov· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a 29-Color Single-Tube Full Spectrum Flow Cytometry Assay for the Detection of Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia.
Zhong Zhang, Miriam Wilhelm, Ines Sieber, Hartmut Döhner, Michaela Feuring

Cytometry A· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic Role of Kidney Disease in Newly Diagnosed Acute Myeloid Leukemia Under Venetoclax-Based Low-Intensity Therapy.
Katja Krüger, Razif Gabdoulline, Martin Wichmann, Bernhard M W Schmidt, Katharina Götze

Cancers (Basel)· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study.
Martha L Arellano, Michael J Thirman, John F DiPersio, Maël Heiblig, Eytan M Stein

Blood· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NOTCH1 signaling is dysregulated by loss of the deubiquitinase USP28 with del(11q), uncovering USP28 inhibition as novel therapeutic target in CLL.
Alena Sophie Ehrmann, Miguel Quijada-Álamo, Viola Close, Min Guo, Valentina Carracoi

Leukemia· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A pooled analysis of 3 large multicenter trials confirms a survival advantage for AML in MRD remission after intensive induction.
Konstanze Döhner, Hartmut Döhner, Daniela Späth, Silke Kapp-Schwoerer, Amanda Gilkes

Hemasphere· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhancer Hijacking Discovery in Acute Myeloid Leukemia by Pyjacker Identifies MNX1 Activation via Deletion 7q.
Etienne Sollier, Anna Riedel, Umut H Toprak, Justyna A Wierzbinska, Dieter Weichenhan

Blood Cancer Discov· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy.
Naval Daver, Paresh Vyas, Gerwin Huls, Hartmut Döhner, Sébastien Maury

Blood· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic impact of clonal representation of myelodysplasia-related gene mutations in acute myeloid leukemia.
Rabea Mecklenbrauck, Nora Borchert, Razif Gabdoulline, Piroska Poll, Carolin Funke

Leukemia· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tailoring intensive and less-intensive treatment in acute myeloid leukemia.
Carolin Seeling, Arnold Ganser, Hartmut Döhner, Michael W M Kühn

Semin Hematol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes with intensive treatment for acute myeloid leukemia: an analysis of two decades of data from the HARMONY Alliance.
Marta Anna Sobas, Amin T Turki, Angela Villaverde Ramiro, Alberto Hernández-Sánchez, Javier Martinez Elicegui

Haematologica· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world experience with first-line CPX-351 treatment in patients with acute myeloid leukemia - long-term follow-up with focus on younger patients.
Christina Rautenberg, Jan Moritz Middeke, Christoph Röllig, Matthias Stelljes, Verena Gaidzik

Blood Cancer J· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Venetoclax and azacitidine in untreated patients with therapy-related acute myeloid leukemia, antecedent myelodysplastic syndromes or chronic myelomonocytic leukemia.
Vinod Pullarkat, Keith W Pratz, Hartmut Döhner, Christian Recher, Michael J Thirman

Blood Cancer J· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acute promyelocytic leukemia: long-term outcomes from the HARMONY project.
Maria Teresa Voso, Luca Guarnera, Söhren Lehmann, Konstanze Döhner, Hartmut Döhner

Blood· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of myelodysplasia-related and additional gene mutations in intensively treated patients with -mutated AML.
Sibylle Cocciardi, Maral Saadati, Nina Weiß, Daniela Späth, Silke Kapp-Schwoerer

Hemasphere· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploiting somatic oncogenic driver alterations in a patient with Li-Fraumeni syndrome- paving the path towards precision medicine: a case report.
Carolin Seeling, Sonja Dahlum, Ralf Marienfeld, Vera Jan, Brigitte Rack

J Cancer Res Clin Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Cancer care in German centers of excellence during the first 2 years of the COVID-19 pandemic.
Volker Arndt, Daniela Doege, Stefan Fröhling, Peter Albers, Hana Algül

J Cancer Res Clin Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Desmoplastic Small Round Cell Tumors: Clinical Presentation, Molecular Characterization, and Therapeutic Approach of Seven Patients.
Verena I Gaidzik, Regine Mayer-Steinacker, Mathias Wittau, Markus Schultheiß, Alexandra V Baer

Sarcoma· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis